PT - JOURNAL ARTICLE AU - Theresa L. Wampler Muskardin AU - Wei Fan AU - Zhongbo Jin AU - Mark A. Jensen AU - Jessica M. Dorschner AU - Yogita Ghodke-Puranik AU - Betty Dicke AU - Danielle Vsetecka AU - Kerry Wright AU - Thomas Mason AU - Scott Persellin AU - Clement J. Michet AU - John M. Davis AU - Eric Matteson AU - Timothy B. Niewold TI - Distinct single cell gene expression in peripheral blood monocytes correlates with tumor necrosis factor inhibitor treatment response groups defined by type I interferon in rheumatoid arthritis AID - 10.1101/19011460 DP - 2020 Jan 01 TA - medRxiv PG - 19011460 4099 - http://medrxiv.org/content/early/2020/02/03/19011460.short 4100 - http://medrxiv.org/content/early/2020/02/03/19011460.full AB - Previously, we demonstrated that type I IFN (IFNβ/α) activity can predict non-response to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). In this study, we examine the biology of TNFi non-response in monocytes from RA patients. We compared single cell gene expression in purified classical (CL, n=342) and non-classical (NC, n=359) monocytes. RA patients were grouped according to their pre-TNFi IFNβ/α activity: those likely to have EULAR no response (non-response group, IFNβ/α 0 or >1.3, n=9) and those likely to have EULAR moderate or good response (response group, IFNβ/α > 0 and ≤1.3, n=6). Major differences in gene expression were apparent in principal component and unsupervised cluster analyses. CL monocytes from the non-response group were unlikely to express JAK1 and IFI27 (p <0.0001 and p 0.0005, respectively). In NC monocytes from the same group, expression of IFNAR1, IRF1, TNFA, TLR4 (p ≤0.0001 for each) and others was enriched. Interestingly, JAK1 expression was absent in CL and NC monocytes from 9 patients. This pattern strongly associated with the non-response IFNβ/α group, suggesting a major biological difference between JAK1 expressors and non-expressors. The type I IFN activity that was previously found to predict TNFi response associated with changes in gene expression in monocytes that suggest differential IFN pathway activation in RA patients who are either likely to respond or to have no response to TNFi. This work could suggest mechanisms for TNFi non-response, and potential therapeutic strategies for those patients unlikely to respond to TNFi.Competing Interest StatementDr. Niewold holds research grants from EMD Serono and Microdrop, Inc. which are not related to this study. Drs. Niewold and Wampler Muskardin have filed a patent on biomarker testing for the prediction of drug response in rheumatoid arthritis.Funding StatementTWM: Arthritis National Research Foundation Arthritis Research Award; NYU Colton Center for Autoimmunity; NYU Department of Medicine Sapperstein Scholar Award; NYU CTSI Scholar Award; Central Society for Clinical and Translational Medicine Career Development Award; Mayo Clinic Career Development Award in Rheumatoid Arthritis Research; TBN: NIH (AR060861, AR057781, AR065964, DK107984), Rheumatology Research Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in this manuscript is available upon reasonable request.